AI Insight
A new oral medication called AZD5462, which acts as a relaxin agonist, demonstrated improvement in cardiac function among patients with chronic heart failure in an early phase clinical trial. The results were presented at ESC Congress 2026 and simultaneously published in the peer-reviewed journal Circulation, indicating positive effects on heart performance in this patient population.
Why it matters
This represents a potential new treatment option for chronic heart failure patients, a condition affecting millions worldwide with limited therapeutic options. The oral administration route could offer advantages over existing therapies in terms of patient convenience and compliance.
Understand the Science
The oral relaxin agonist AZD5462 improved cardiac function in patients with chronic heart failure, according to results presented in a Hot Line session at ESC Congress 2026 and published simultaneously in Circulation.
Source: Novel drug shows promise in an early phase trial in heart failure